Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 2
2009 3
2010 2
2012 1
2013 1
2014 2
2015 1
2016 4
2017 2
2018 2
2019 7
2020 2
2021 4
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for sotaro enatsu
Search for Kotaro Ematsu instead (1 results)
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Nakagawa K, et al. Among authors: enatsu s. Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4. Lancet Oncol. 2019. PMID: 31591063 Clinical Trial.
Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study).
Nishio K, Sakai K, Nishio M, Seto T, Visseren-Grul C, Carlsen M, Matsui T, Enatsu S, Nakagawa K. Nishio K, et al. Among authors: enatsu s. Transl Lung Cancer Res. 2023 Aug 30;12(8):1702-1716. doi: 10.21037/tlcr-22-736. Epub 2023 Aug 10. Transl Lung Cancer Res. 2023. PMID: 37691865 Free PMC article.
[Drug interactions in medical oncology].
Ishiguro H, Koshiji M, Morizane T, Taniai H, Enatsu S, Fujimoto T, Nambu Y. Ishiguro H, et al. Among authors: enatsu s. Gan To Kagaku Ryoho. 2009 May;36(5):879-85. Gan To Kagaku Ryoho. 2009. PMID: 19461200 Review. Japanese.
Possible applications of antibodies or their genes in cancer therapy.
Kuroki M, Huang J, Shibaguchi H, Tanaka T, Zhao J, Luo N, Hachimine K, Kinugasa T, Maekawa S, Enatsu S, Hamanaka W, Fukami T, Kuroki M. Kuroki M, et al. Among authors: enatsu s. Anticancer Res. 2006 Nov-Dec;26(6A):4019-25. Anticancer Res. 2006. PMID: 17195452 Free article. Review.
RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC.
Nishio M, Nishio K, Reck M, Garon EB, Imamura F, Kawaguchi T, Yamaguchi H, Ikeda S, Hirano K, Visseren-Grul C, Ceccarelli M, Wijayawardana SR, Zimmermann A, Matsui T, Enatsu S, Nakagawa K. Nishio M, et al. Among authors: enatsu s. JTO Clin Res Rep. 2022 Feb 26;3(4):100303. doi: 10.1016/j.jtocrr.2022.100303. eCollection 2022 Apr. JTO Clin Res Rep. 2022. PMID: 35369607 Free PMC article.
Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.
Nishio M, Seto T, Reck M, Garon EB, Chiu CH, Yoh K, Imamura F, Park K, Shih JY, Visseren-Grul C, Frimodt-Moller B, Zimmermann A, Homma G, Enatsu S, Nakagawa K; RELAY Study Investigators. Nishio M, et al. Among authors: enatsu s. Cancer Sci. 2020 Dec;111(12):4510-4525. doi: 10.1111/cas.14655. Epub 2020 Oct 14. Cancer Sci. 2020. PMID: 32954593 Free PMC article. Clinical Trial.
34 results